Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Rhea-AI Summary

Harrow (HROW) reported strong financial results for Q4 and full-year 2024. The company achieved record Q4 revenues of $66.8 million, up 84% year-over-year, while full-year 2024 revenues reached $199.6 million, representing a 53% increase from 2023.

Q4 2024 highlights include GAAP net income of $6.8 million and Adjusted EBITDA of $22.5 million. For the full year 2024, the company reported a GAAP net loss of $(17.5) million and Adjusted EBITDA of $40.3 million.

Notable operational achievements include over 40% quarter-over-quarter growth in both IHEEZO unit demand and VEVYE prescriptions. The company announced its VEVYE Access for All program to drive market share expansion in 2025. Additionally, TRIESENCE received transitional pass-through approval, significantly expanding its market opportunity. Management provided 2025 revenue guidance of 'more than $280 million,' projecting over 40% growth.

Positive

• Record Q4 2024 revenue of $66.8M, up 84% YoY
• Full-year 2024 revenue of $199.6M, up 53% YoY
• Q4 2024 GAAP net income of $6.8M
• Q4 2024 Adjusted EBITDA of $22.5M
• 40%+ QoQ growth in IHEEZO and VEVYE product demand
• TRIESENCE transitional pass-through approval expanding market opportunity
• Strong 2025 revenue guidance of >$280M (40%+ growth)

Negative

• Full-year 2024 GAAP net loss of $(17.5M)

Insights

Financial Analyst

Harrow's Q4 2024 results represent exceptional financial performance, with record quarterly revenue of $66.8 million marking an 84% year-over-year increase. The company achieved full-year revenue of $199.6 million, up 53% from 2023. The transition to profitability in Q4 ($6.8 million GAAP net income) is particularly significant despite the full-year GAAP net loss of $(17.5) million.

The strong Adjusted EBITDA of $22.5 million for Q4 and $40.3 million for 2024 indicates improving operational efficiency. The robust product uptake is evident in the 40%+ quarter-over-quarter growth for both IHEEZO unit demand and VEVYE prescriptions, suggesting strong market acceptance of Harrow's expanding portfolio.

Management's 2025 revenue guidance of "more than $280 million" (representing 40%+ growth) demonstrates confidence in continued momentum. Key growth catalysts include the VEVYE Access for All program and the CMS approval of transitional pass-through status for TRIESENCE, which substantially expands its addressable market by improving reimbursement pathways.

This appears to be an inflection point for Harrow, with Q4 potentially marking the transition from growth-focused investment to profitable expansion. The combination of established product momentum, expanded market access, and potential pipeline additions positions the company for continued strong performance through 2025.

Fourth-Quarter, Full-Year 2024, and Recent Highlights:

• Record revenues of $66.8 million for Q4 2024, an 84% increase over Q4 2023
• Revenues of $199.6 million for FY 2024, a 53% increase over FY 2023
• GAAP net income of $6.8 million for Q4 2024, for a GAAP net loss of $(17.5) million for FY 2024
• Adjusted EBITDA of $22.5 million for Q4 2024, leading to Adjusted EBITDA of $40.3 million for FY 2024
• IHEEZO® unit demand and VEVYE® prescriptions for Q4 2024 each increased over 40% over Q3 2024
• VEVYE® Access for All program expected to drive continued market share expansion in 2025
• TRIESENCE® transitional pass-through approved, significantly increasing addressable market opportunity

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2024. The Company also posted its fourth quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations for the business.

“Our stellar fourth-quarter performance, including an 84% year-over-year increase in revenues to a record $66.8 million, marked the end of a monumental year for Harrow, with 2024 revenues rising 53% over 2023 to $199.6 million,” said Mark L. Baum, Chief Executive Officer of Harrow. “This strong finish, driven by over 40% quarter-over-quarter growth in both IHEEZO unit demand and VEVYE prescriptions, showcases market uptake for our expanding portfolio and the overall success of the Harrow team. We expect our momentum to continue in 2025, particularly in the second half, as the recently announced VEVYE Access for All program gains traction – accelerating market share capture, expanding commercially covered prescriptions, and bolstering prescriber confidence by ensuring their patients can affordably start treatment with VEVYE, regardless of insurance status. Meanwhile, in addition to our success in stabilizing the supply chain for TRIESENCE, the Centers for Medicare & Medicaid Services recently approved our transitional pass-through application, significantly increasing its addressable market. This terrific news should add fuel to our commercial efforts concurrent with our development of a next-generation version of this high-value and high-trust product. Because we remain at the initial stages of market penetration for our core products, we expect revenue growth in these cornerstone products for years to come.”

Baum added, “We continue to review new ways to better serve our customers and leverage our commercial infrastructure by adding attractive low-risk, high-return products. This includes product candidates we have been quietly nurturing internally, which we expect to discuss in more detail later this year; those being brought to us by third parties; and those in which we already have a stake, such as the MELT-300 program. Finally, Harrow stockholders should know that while we expect normal seasonal revenue fluctuations, we are confident in the remainder of 2025, as demonstrated by our 2025 revenue guidance of ‘more than $280 million,’ representing an increase over 2024 revenue of more than 40% in annual revenues.”

Fourth-quarter and year-end 2024 figures of merit:

	For the Three Months Ended December 31,								For the Year Ended December 31,
		2024				2023				2024				2023
Total revenues	$	66,831,000			$	36,355,000			$	199,614,000			$	130,193,000
Gross margin		79	%			69	%			75	%			70	%
Core gross margin(1)		84	%			75	%			80	%			77	%
Net income (loss)		6,777,000				(9,148,000	)			(17,481,000	)			(24,411,000	)
Core net income (loss)(1)		11,366,000				(7,016,000	)			(2,089,000	)			(11,512,000	)
Adjusted EBITDA(1)		22,489,000				2,563,000				40,327,000				28,119,000
Net income (loss) per share:
Basic		0.19				(0.26	)			(0.49	)			(0.75	)
Diluted		0.24				(0.26	)			(0.49	)			(0.75	)
Core net income (loss) per share:(1)
Basic		0.32				(0.20	)			(0.06	)			(0.35	)
Diluted		0.40				(0.20	)			(0.06	)			(0.35	)

(1)

Core gross margin, core net income (loss), core basic and diluted net income (loss) per share (collectively, “Core Results”), and Adjusted EBITDA are non‑GAAP measures. For additional information, including a reconciliation of such Core Results and Adjusted EBITDA to the most directly comparable measures presented in accordance with GAAP, see the explanation of non‑GAAP measures and reconciliation tables at the end of this release.

Conference Call and Webcast

The Company’s management team will host a conference call and live webcast tomorrow morning, Friday, March 28, 2025, at 8:00 a.m. Eastern time to discuss the fourth-quarter and year-end 2024 results and provide a business update. Participants can access the live conference call via webcast on the “Investors” page of Harrow’s website. To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call. A replay of the conference call webcast will be archived on the Company’s website for one year.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward‑looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

HARROW, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
	December 31, 2024			December 31, 2023
	(unaudited)
ASSETS
Cash and cash equivalents	$	47,247,000		$	74,085,000
All other current assets		142,404,000			65,397,000
Total current assets		189,651,000			139,482,000
All other assets		199,320,000			172,682,000
TOTAL ASSETS	$	388,971,000		$	312,164,000
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities	$	91,343,000		$	49,344,000
Loans payable, net of unamortized debt discount		219,539,000			185,885,000
All other liabilities		8,792,000			6,524,000
TOTAL LIABILITIES		319,674,000			241,753,000
TOTAL STOCKHOLDERS' EQUITY		69,297,000			70,411,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	388,971,000		$	312,164,000

HARROW, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
	For the Three Months Ended December 31,								For the Year Ended December 31,
		2024				2023				2024				2023
Total revenues	$	66,831,000			$	36,355,000			$	199,614,000			$	130,193,000
Cost of sales		14,135,000				11,302,000				49,245,000				39,640,000
Gross profit		52,696,000				25,053,000				150,369,000				90,553,000
Selling, general and administrative		34,789,000				26,212,000				129,064,000				83,090,000
Research and development		4,755,000				3,336,000				12,230,000				6,652,000
Impairment of long-lived assets		253,000				380,000				253,000				380,000
Total operating expenses		39,797,000				29,928,000				141,547,000				90,122,000
Income (loss) from operations		12,899,000				(4,875,000	)			8,822,000				431,000
Total other expense, net		(6,636,000	)			(4,808,000	)			(26,142,000	)			(24,141,000	)
Income tax benefit (expense)		514,000				535,000				(161,000	)			(701,000	)
Net income (loss) attributable to Harrow, Inc.	$	6,777,000			$	(9,148,000	)		$	(17,481,000	)		$	(24,411,000	)
Net income (loss) per share:
Basic	$	0.19			$	(0.26	)		$	(0.49	)		$	(0.75	)
Diluted	$	0.24			$	(0.26	)		$	(0.49	)		$	(0.75	)

HARROW, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
	For the Year Ended December 31,
		2024				2023
Net cash (used in) provided by:
Operating activities	$	(22,202,000	)		$	3,840,000
Investing activities		(33,164,000	)			(152,553,000	)
Financing activities		28,528,000				126,528,000
Net change in cash and cash equivalents		(26,838,000	)			(22,185,000	)
Cash and cash equivalents at beginning of the period		74,085,000				96,270,000
Cash and cash equivalents at end of the period	$	47,247,000			$	74,085,000

Non-GAAP Financial Measures

In addition to the Company’s results of operations determined in accordance with U.S. generally accepted accounting principles (GAAP), which are presented and discussed above, management also utilizes Adjusted EBITDA and Core Results, unaudited financial measures that are not calculated in accordance with GAAP, to evaluate the Company’s financial results and performance and to plan and forecast future periods. Adjusted EBITDA and Core Results are considered “non‑GAAP” financial measures within the meaning of Regulation G promulgated by the SEC. Management believes that these non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results, provide a more complete understanding of the Company’s results of operations and the factors and trends affecting its business. Management believes Adjusted EBITDA and Core Results provide meaningful supplemental information regarding the Company’s performance because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making; (ii) they exclude the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company’s core operating performance and that may obscure trends in the Company’s core operating performance; and (iii) they are used by institutional investors and the analyst community to help analyze the Company’s results. However, Adjusted EBITDA, Core Results, and any other non‑GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non‑GAAP financial measures used by the Company and the way they are calculated may differ from the non-GAAP financial measures or the calculations of the same non‑GAAP financial measures used by other companies, including the Company’s competitors.

Adjusted EBITDA

The Company defines Adjusted EBITDA as net income (loss), excluding the effects of stock‑based compensation and expenses, impairment of intangible assets, interest, taxes, depreciation, amortization, investment (income) loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net income (loss). Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net loss as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs.

The following is a reconciliation of Adjusted EBITDA, a non-GAAP measure, to the most comparable GAAP measure, net income (loss), for the three months and year ended December 31, 2024 and for the same periods in 2023:

HARROW, INC.
RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA
	For the Three Months Ended December 31,									For the Year Ended December 31,
		2024				2023						2024						2023
GAAP net income (loss)	$	6,777,000			$	(9,148,000	)			$		(17,481,000	)			$		(24,411,000	)
Stock-based compensation and expenses		4,794,000				4,175,000						17,619,000						15,696,000
Impairment of intangible assets		253,000				380,000						253,000						380,000
Interest expense, net		6,375,000				5,124,000						22,786,000						21,324,000
Income tax (benefit) expense		(514,000	)			(535,000	)					161,000						701,000
Depreciation		468,000				435,000						1,850,000						1,530,000
Amortization of intangible assets		4,075,000				2,448,000						11,783,000						10,082,000
Investment (income) loss, net		-				(416,000	)					3,171,000						(3,092,000	)
Loss on disposal of equipment		-				146,000						-						168,000
Other expense (income), net		261,000				(46,000	)					185,000						5,741,000	(1)
Adjusted EBITDA	$	22,489,000			$	2,563,000				$		40,327,000				$		28,119,000
(1) Includes $5,465,000 for the loss on extinguishment of debt.

Core Results

Harrow Core Results, including core gross margin, core net income (loss), and core basic and diluted income (loss) per share exclude (1) all amortization and impairment charges of intangible assets, excluding software development costs, (2) net gains and losses on investments and equity securities, including equity method gains and losses and equity valued at fair value through profit and loss (FVPL), and preferred stock dividends, and (3) gains/losses on forgiveness of debt. In certain periods, Core Results may also exclude fair value adjustments of financial assets in the form of options to acquire a company carried at FVPL, obligations related to product recalls, certain acquisition‑related items, restructuring charges/releases and associated items, related legal items, gains/losses on early extinguishment of debt or debt modifications, impairments of property, plant and equipment and software, as well as income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a $100,000 threshold.

The following is a reconciliation of Core Results, non-GAAP measures, to the most comparable GAAP measures for the three months and year ended December 31, 2024 and for the same periods in 2023:

For the Three Months Ended December 31, 2024
	GAAP Results				Amortization of Certain Intangible Assets			Impairments			Investment Gains (Losses)			Other Items			Core Results
Gross profit	$	52,696,000			$	3,622,000		$	-		$	-		$	-		$	56,318,000
Gross margin		79	%															84	%
Operating income		12,899,000				4,075,000			253,000			-			-			17,227,000
Income before taxes		6,263,000				4,075,000			253,000			-			261,000			10,852,000
Taxes		514,000				-			-			-			-			514,000
Net income		6,777,000				4,075,000			253,000			-			261,000			11,366,000
Income per share ($)(1):
Basic		0.19																0.32
Diluted		0.24																0.40
Weighted average number of shares of common stock outstanding:
Basic		35,807,767																35,807,767
Diluted		28,317,740																28,317,740

For the Year Ended December 31, 2024
	GAAP Results				Amortization of Certain Intangible Assets			Impairments			Investment Gains (Losses)			Other Items			Core Results
Gross profit	$	150,369,000			$	10,093,000		$	-		$	-		$	-		$	160,462,000
Gross margin		75	%															80	%
Operating income		8,822,000				11,783,000			253,000			-			-			20,858,000
(Loss) income before taxes		(17,320,000	)			11,783,000			253,000			3,171,000			185,000			(1,928,000	)
Tax expense		(161,000	)			-			-			-			-			(161,000	)
Net (loss) income		(17,481,000	)			11,783,000			253,000			3,171,000			185,000			(2,089,000	)
Basic and diluted loss per share ($)(1)		(0.49	)															(0.06	)
Weighted average number of shares of common stock outstanding, basic and diluted		35,650,714																35,650,714

For the Three Months Ended December 31, 2023
	GAAP Results				Amortization of Certain Intangible Assets			Impairments			Investment Gains (Losses)				Other Items			Core Results
Gross profit	$	25,053,000			$	2,140,000		$	-		$	-			$	-		$	27,193,000
Gross margin		69	%																75	%
Operating (loss) income		(4,875,000	)			2,448,000			-			-				-			(2,427,000	)
(Loss) income before taxes		(9,683,000	)			2,448,000			-			(416,000	)			100,000			(7,551,000	)
Tax benefit		535,000				-			-			-				-			535,000
Net (loss) income		(9,148,000	)			2,448,000			-			(416,000	)			100,000			(7,016,000	)
Basic and diluted loss per share ($)(1)		(0.26	)																(0.20	)
Weighted average number of shares of common stock outstanding, basic and diluted		35,353,848																	35,353,848

For the Year Ended December 31, 2023
	GAAP Results				Amortization of Certain Intangible Assets			Impairments			Investment Gains (Losses)				Other Items			Core Results
Gross profit	$	90,553,000			$	9,314,000		$	-		$	-			$	-		$	99,867,000
Gross margin		70	%																77	%
Operating income		431,000				10,082,000			-			-				-			10,513,000
(Loss) income before taxes		(23,710,000	)			10,082,000			-			(3,092,000	)			5,909,000			(10,811,000	)
Tax expense		(701,000	)			-			-			-				-			(701,000	)
Net (loss) income		(24,411,000	)			10,082,000			-			(3,092,000	)			5,909,000			(11,512,000	)
Basic and diluted loss per share ($)(1)		(0.75	)																(0.35	)
Weighted average number of shares of common stock outstanding, basic and diluted		32,616,777																	32,616,777
(1) Core basic and diluted income (loss) per share is calculated using the weighted-average number of shares of common stock outstanding during the period. Core basic and diluted income (loss) per share also contemplates dilutive shares associated with equity‑based awards as described in Note 2 and elsewhere in the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250327714911/en/

Jamie Webb, Director of Communications and Investor Relations

jwebb@harrowinc.com

615-733-4737

Source: Harrow, Inc.

FAQ

What was Harrow's (HROW) revenue growth in Q4 2024?

Harrow achieved record Q4 2024 revenues of $66.8 million, representing an 84% increase compared to Q4 2023.

How much revenue did HROW generate in full-year 2024?

Harrow generated $199.6 million in revenue for full-year 2024, a 53% increase over full-year 2023.

What is Harrow's revenue guidance for 2025?

Harrow projects 2025 revenue to exceed $280 million, representing over 40% growth compared to 2024.

How did HROW's key products IHEEZO and VEVYE perform in Q4 2024?

Both IHEEZO unit demand and VEVYE prescriptions increased by over 40% in Q4 2024 compared to Q3 2024.

What was HROW's profitability status in Q4 and full-year 2024?

HROW reported Q4 2024 GAAP net income of $6.8 million, but had a full-year 2024 GAAP net loss of $(17.5) million.